Drug Trial Radar · NCT05639647
Study of 2 Medicines (Aztreonam and Avibactam) Compared to Best Available Therapy for Serious Gram-negative Infections
Last checked: Nov 20, 2026Latest source record: Oct 29, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
48
Planned (sponsor's estimate)
Start
Apr 18, 2023
Primary completion
Mar 31, 2027
Study completion Mar 31, 2027
Sponsor
- Lead sponsor
- PfizerPfizer (PFE)
- Sponsor type
- Industry
- First posted
- Dec 6, 2022
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Single (investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 9 months, up to 17 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to evaluate how Aztreonam (ATM) and Avibactam (AVI) are processed in pediatric participants. This study also aims to understand participant safety and effects in pediatric participants. The study is seeking participants who are: * 9 months to less than 18 years of age * Hospitalized * Suspected/known to have a gram-negative infection * Receiving intravenous (iv, given directly into a vein) antibiotics * Being treated for complicated infections of various body parts that includes the abdomen, urinary tract, blood stream, and lungs. * Participants will receive either ATM-AVI or best available therapy (BAT). * Both therapies will be given through a vein. * Participants with complicated abdominal infections will also receive iv Metronidazole (MTZ). Patients with cIAI and Cockayne Syndrome are excluded due to a risk of severe hepatotoxicity with the use of MTZ. - Participants on ATM-AVI treatment who have anaerobic infections will also receive iv MTZ at the study doctor's discretion. * The iv dose of ATM-AVI will be based on the participant's weight and kidney function. * The study doctor will determine the iv dose of BAT. * During the first 2 study days, participants on ATM-AVI therapy will have 5 blood draws in small quantities. * Starting on day 4, the study doctor will decide if participants may be switched to oral therapy. * Participants will receive a maximum of 14 days of ATM-AVI treatment. * After discharge from the hospital, 1 study visit may be required. * Depending on the participant's response, the study duration will be from 33 to 50 days. * The investigator will contact participants by phone 28 to 35 days after the last study treatment to check participants health status.
Conditions
- Gram-negative Bacterial Infections
Interventions
ATM-AVIDrug
A drug specifically designed to treat resistant gam-negative bacterial infections
BATDrug
BAT will be selected by the investigator and administered iv as appropriate for the selected drug(s)
Primary outcomes
What the sponsor says the trial is designed to measure.
- Maximum Predicted Plasma Concentration (Cmax) of ATM and AVITime frame: Up to 15 Days
- Minimum Predicted Trough Plasma Concentration (Cmin) of ATM and AVITime frame: Up to 15 Days
- Area under the Concentration-Time Curve (AUC) of ATM-AVITime frame: Up to 15 Days
- Plasma Decay Half-Life (t1/2)Time frame: Up to 15 Days
- Apparent Clearance (CL)Time frame: Up to 15 Days
- Proportion of Participants reporting Adverse Events (AE)Time frame: Baseline up to Day 50
- Proportion of Participants reporting Serious Adverse Events (SAE)Time frame: Baseline up to Day 50
- Proportion of Participants reporting AEs leading to discontinuationTime frame: Baseline up to Day 50
- Proportion of Participants reporting AEs resulting in deathTime frame: Baseline up to Day 50
- Proportion of Participants reporting liver injury and acute kidney injury of ATM-AVI relative to Best Available Therapy (BAT)Time frame: Baseline up to Day 50
Locations
22 sites in 8 countries. Site status is shown where the registry gives one.
Rady Children's Hospital
San Diego, California · Recruiting
Weill Cornell Medicine-New York Presbyterian Hospital
New York, New York · Recruiting
Icahn School of Medicine at Mount Sinai
New York, New York · Recruiting
Shanghai Children's Medical Center
Shanghai, China · Recruiting
Beijing Children's Hospital, Capital Medical University
Beijing, Beijing Municipality, China · Recruiting
Guangzhou Women and Children's Medical Center
Guangzhou, Guangdong, China · Recruiting
University General Hospital of Heraklion
Heraklion, Irakleío, Greece · Recruiting
Ippokrateio General Hospital of Thessaloniki
Thessaloniki, Kentrikí Makedonía, Greece · Recruiting
Semmelweis Egyetem
Budapest, Hungary · Recruiting
RajaRajeswari Medical College and Hospital
Bangalore, Karnataka, India · Recruiting
Medanta Hospital Lucknow
Lucknow, Uttar Pradesh, India · Recruiting
Institute of Child Health
Kolkata, West Bengal, India · Recruiting
Hospital Universitari Vall d'Hebron
Barcelona, Spain · Recruiting
Hospital Universitario 12 de Octubre
Madrid, Spain · Recruiting
Hospital Germans Trias i Pujol
Badalona, Barcelona [barcelona], Spain · Recruiting
Hospital Sant Joan de Déu
Esplugues de Llobregat, Barcelona [barcelona], Spain · Recruiting
Hospital Universitario La Paz
Madrid, Madrid, Comunidad de, Spain · Recruiting
National Taiwan University Hospital
Taipei, Taiwan · Recruiting
Chang Gung Medical Foundation-Linkou Branch
Taoyuan, Taiwan · Recruiting
Hsinchu Municipal Mackay Children's Hospital
Hsinchu, Hsinchu, Taiwan · Recruiting
Cukurova Universty
Sarçam, Adana, Turkey (Türkiye) · Active not recruiting
Istanbul Universitesi Istanbul Tıp Fakultesi Hastanesi
Istanbul, İ̇stanbul, Turkey (Türkiye) · Active not recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.